Dragon Boat festival

　

Zongqing Zongyi Dragon Boat Festival Ankang

　

Dragon Boat Festival

　

　

　

Dragon Boat Festival is the fifth day of the fifth lunar month, also known as Duanyang Festival, which is one of the four traditional festivals in China. On this day, people will race dragon boats, eat zongzi and hang wormwood. The Dragon Boat Festival culture has a wide influence in the world, and some countries and regions in the world also celebrate the Dragon Boat Festival. In September 2009, UNESCO officially approved its inclusion in the List of Representatives of the Intangible Cultural Heritage of Humanity, making the Dragon Boat Festival the first non-legacy festival in China.

　

　

The origin of the Dragon Boat Festival

　

It is said that the custom of eating zongzi and racing dragon boats on the Dragon Boat Festival is to commemorate Qu Yuan, a great poet in Chinese history. It is precisely because of this that the Dragon Boat Festival was named "Poet’s Day" after the founding of New China.

　

Qu Yuan is one of the greatest romantic poets in China, the earliest known famous poet in China and a world cultural celebrity. He created the style of "Chu Ci" and the tradition of "vanilla beauty". Representative works include Li Sao and Nine Songs.

　

In the history of our country, the saying that the Dragon Boat Festival is to commemorate Qu Yuan has a history of more than 1500 years. According to legend, after Qu Yuan threw himself into the Miluo River, the local people immediately rowed for rescue and went all the way to Dongting Lake, but Qu Yuan’s body was never seen. At that time, it was rainy, and the boats on the lake gathered together beside the pavilion on the shore. When people learned that it was to salvage the virtuous minister Dr. Qu, they went out in the rain again and rushed into the vast Dongting Lake. In order to mourn, people rowed on the rivers, and then it gradually developed into a dragon boat race. The people were afraid that the fish in the river would eat his body, so they went home to bring rice balls and throw them into the river to prevent fish and shrimp from ruining Qu Yuan’s body. Later, it became the custom to eat zongzi.

　

The customs of the Dragon Boat Festival

　

　

First, dragon boat race

　

Dragon boat race is the main custom of the Dragon Boat Festival. According to legend, it originated in ancient times, because Chu people could not bear to part with Qu Yuan, a worthy minister, and died in the river, many people rowed to catch up and save. They scrambled to catch up with each other until Dongting Lake disappeared. After that, I will row a dragon boat on May 5th every year to commemorate it. People use dragon boats to disperse the fish in the river so as not to eat Qu Yuan’s body. The habit of racing is prevalent in Wu, Yue and Chu.

　

　

Second, eat zongzi

　

Eating zongzi on Dragon Boat Festival is another traditional custom of Chinese residents. Zongzi, also known as "horn millet" and "tube zongzi". It has a long history and various patterns. On the morning of Dragon Boat Festival, families eat zongzi to commemorate Qu Yuan. Generally, they wrap zongzi the day before, cook them at night and eat them in the morning. Dumplings are mainly made of tender reed leaves which are abundant along the river pond, and bamboo leaves are also useful in some areas, collectively called zongye. The traditional form of zongzi is triangle, which is generally named after the inner pulp. The glutinous rice dumplings are called rice dumplings, the ones mixed with adzuki beans are called adzuki dumplings, and the ones mixed with red dates are called jujube dumplings, which are collectively called glutinous rice dumplings. Jujube dumplings are homophonic for "early middle school", so they are eaten the most, and children who intend to study can win the championship early. In the past, scholars used to eat jujube dumplings in the morning on the day of taking the imperial examination. Up to now, parents have to make jujube dumplings for candidates on the morning of the entrance examination day for middle schools and universities, wishing them a good school.

　

　

Third, tie colorful ropes and wear sachets

　

Five-color lines are mainly composed of five colors: green, red, white, black and yellow. These five colors are called auspicious colors, and they can be worn on the Dragon Boat Festival to keep you safe. Later, the custom of tying colorful ropes gradually evolved into hanging sachets, and children wore sachets on the Dragon Boat Festival. Legend has it that it meant to ward off evil spirits and drive away plague (in ancient times, people thought that they were sick because of monsters and ghosts), but it was actually used to decorate the inner head. The sachet contains cinnabar, realgar and fragrant medicine, wrapped with silk cloth, which is full of fragrance, and then tied with five-color silk threads to form a rope, making a string in various shapes, all kinds of shapes, small and lovely. In some southern cities of China, young men and women also use sachets to express their deep love.

　

　

　

erect

　

noon

　

safe

　

healthy

　

Four, hanging wormwood and calamus

　

A folk proverb says, "Willows are inserted in Qingming Festival, and Ai is inserted in Dragon Boat Festival". On the Dragon Boat Festival, people regard inserting wormwood and calamus as one of the important contents. Every household should sweep the courtyard and put calamus and moxa sticks in the lintel and hang them in the hall. Acorus calamus, Folium Artemisiae Argyi, Liuhua, Bulbus Allii and Dragon Boat Flower are made into human or tiger shapes, which are called Ai Ren and Ai Hu. It is made into garlands and ornaments, which are beautiful and fragrant, and women compete to wear them to drive away evil. Dragon Boat Festival is also a "health festival" handed down from ancient times. On this day, people sweep the courtyard, hang mugwort, hang calamus, sprinkle realgar water, drink realgar wine, stir up turbidity, remove rot, sterilize and prevent diseases. They are considered to have the effect of exorcising evil spirits and protecting the health and safety of family members.

　

　

Fifth, order realgar wine

　

Realgar is also a kind of medicinal material, which is said to kill all kinds of poisons. Therefore, during the Dragon Boat Festival, Shaanxi people will soak realgar in wine and put realgar wine on children’s ears, nose, forehead, wrists and ankles. It is said that this practice can keep mosquitoes, snakes, scorpions, centipedes, geckos and spiders off their bodies.

　

　

Six, eat salted duck eggs

　

Eating salted duck eggs on the Dragon Boat Festival is a big custom. As the saying goes, "You have to eat salted egg zongzi to send the chill." After the Dragon Boat Festival, it indicates that the hot summer is coming, and the activities of animals and plants have entered a vigorous stage. In addition, the humid climate and the active diseases, pests and bacteria are easy to cause many diseases. Eating salted duck eggs on the Dragon Boat Festival can detoxify and help keep healthy.

　

　

The contents of the Dragon Boat Festival customs are rich and varied, including polo, grass fighting, painting, flying kites, and there are some small differences in details because of different regional cultures throughout the country.

　

Do you understand the origin and customs of the Dragon Boat Festival?

　

Wechat has been revised recently.

　

Readers and friends often miss the push.

　

Star sign "Beijing Charity Volunteer"

　

Receive the latest tweets in time

　

　

Source: Cultural Accompanying WeChat WeChat official account

　

Editor: Propaganda Office　

　

　　Recently, the information about the invasion of online courses in many places has attracted much attention.

　　According to Beijing Youth Daily, on September 5th, students of Shenyang Institute of Urban Construction, Liaoning Province were maliciously intruded by others while surfing the Internet, and swiping the screen "I love you, teacher" disturbed the classroom order. Chengdu Business Daily-Red Star News reporter noticed that students in many places in China said that they had been invaded by online classes: when students were surfing the Internet through Tencent conferences, nails and other platforms, some strangers suddenly poured into the live broadcast room, some people abused teachers and students, some people played funeral music, and even distributed obscene pornographic videos.

　　Fu Jian, a lawyer of Henan Yulong Law Firm, said that in the online class, he publicly insulted others, derogated from others’ personality, and was suspected of infringing on the right of reputation, and was also suspected of violating the Law on Public Security Administration Punishment; If you distribute obscene pornographic videos, you are suspected of spreading obscene articles, and the criminal responsibility of the disseminator should be investigated according to law.

　　Who’s involved?

　　Some netizens set up QQ group to exchange "invasion experience"

　　On September 7th, the reporter used "online class explosion" and "online class invasion" as the key words, and found on several social platforms that many netizens with domestic IP addresses said that they were inexplicably invaded by strangers during online class, and the intruders interfered with the class and made many excessive things, such as opening wheat to make noise, insulting students and teachers, playing funeral music, telling obscene jokes and distributing obscene pornographic videos. Some online classes will suddenly break into 20 or 30 people, who use the names of some online hot words or famous stars as ID names and publish some unbearable remarks.

　　The reporter used "meeting" as the key word to search for groups on QQ, and immediately joined several QQ groups. The reporter found that people in QQ group often send Tencent meetings or nail the meeting number and password, and some group friends directly forward the meeting link in the group. Click on the link to see that the group name is "Meeting Room of Class Four, Grade Two" and so on.

　　One of the more active groups, the group administrator often sends such a paragraph: "You can’t provoke the teacher in the live broadcast room, you can ignore the teacher. No yellowing (pictures, videos) and no abuse. Play and play, make trouble, don’t make fun of the law. "

　　A group friend told reporters that he had been playing "online class invasion" for three days and shared his "experience" — — When you enter the online class, you don’t want to make pornographic pictures, swear, or go too far. You can play songs. If the teacher calls the police, you should leave the meeting quickly, so you don’t have to worry about being investigated by the police or being banned.

　　In these so-called intruders’ QQ groups, friends in the group will chat and exchange information about the invasion, take pictures or videos of their own invasion and send them to the group, and some people will send online class information to the group for everyone to join … … The reporter noticed that in a QQ group of this kind, a netizen named "Xiaofei" is very active. If a netizen reminds students in the group not to invade online classes in Grade Three or Grade Three, he will speak and say, "What does it matter if they can’t get into high school and college?" He said that he had dropped out of school.

　　Up to now, some QQ groups have been dissolved, and reporters have reported the remaining QQ groups one by one.

　　Online students:

　　It may be a classmate who leaked the meeting number and password.

　　Xiao An, a sophomore in Sichuan, told reporters that he was very angry because his class was also invaded on September 5. At that time, they were having a class, and suddenly two or three people came in, forced to turn on the microphone, or played music or abused teachers and students. The intruder also said that some students in the class posted the meeting number and password on the social platform, and they saw the information before entering the conference room.

　　The intruder stayed in Xiao ‘an’s class for more than 10 minutes, so the teacher had to turn off the microphones of all the staff. These people went to the chat area to insult the students. Xiao An said that the online class meeting number and password can now be searched on some social platforms, and some people leaked the information at will. In Xiao ‘an’s view, it may be students who leak information, perhaps for fun or because they don’t want to study.

　　Teacher Wu, a high school teacher in a school in Sichuan, told reporters that she knew that three colleagues had been invaded while surfing the Internet through the nail platform recently. Many intruders will burst into the classroom inexplicably, either talking nonsense or talking nonsense on the public screen. In the class of one of Mr. Wu’s colleagues, dozens of people suddenly poured into the online class meeting room, all smoking with bare arms.

　　Teacher Wu said that it is wrong for intruders to do this for whatever reason. She hopes that these meeting numbers and meeting passwords are not provided by students. In order to prevent the invasion of online classes, Ms. Wu also spent time studying how to take online classes. For example, she prefers to set permissions through Tencent meetings. But this also has disadvantages. If the host doesn’t notice that a student has entered the meeting, this person will not be able to attend the meeting in time.

　　Public security organs:

　　Attention has been paid to the phenomenon of online course intrusion.

　　The reporter noticed that the network police in Shenzhen and Tianjin have voiced through Weibo, saying that they are concerned about the invasion of online classes.

　　The media reporter also consulted the customer service of several online live broadcast platforms, and some customer service responded that "in this case, you can submit a report and feedback" and "no relevant complaints have been received at present. If the situation is true, the platform will ban the relevant accounts".

　　The reporter noted that as early as the beginning of 2020, WeChat official account, the official WeChat of the Network Security Bureau of the Ministry of Public Security, had issued a document stressing the safety of online classes. It is mentioned that all kinds of educational mobile Internet applications (referred to as educational apps) are booming, but they also increase the original security risks. The online "cloud classroom" has become an important channel for the majority of primary and secondary school students to learn online during the epidemic prevention and control period. However, some online class platforms in primary and secondary schools pop up advertisements during class, and even appear illegal and harmful information such as pornographic gambling, which seriously undermines the online education and teaching order and infringes on the physical and mental health of minors.

　　The network security department of the public security organ helps the online classroom, actively cooperates with the education authorities, strengthens safety supervision according to their duties, organizes all parties to carry out safety protection, and cracks down on illegal and criminal acts according to law. The public security organs will resolutely investigate and deal with the acts of publishing and disseminating illegal and harmful information related to pornography and gambling. We will crack down on suspected criminal offences according to law, fully purify the online environment, and earnestly safeguard network security.

　　Zhao Zhanling, a lawyer of Beijing Yunjia Law Firm, said that the legal liability of the participants in the online class invasion mainly depends on their specific behaviors. If the intruder insults teachers and students, it may only constitute a civil tort and infringe on the reputation rights of teachers and students. If you play obscene articles, you may be suspected of a criminal offence. It is not illegal or criminal to disturb the classroom by talking more and playing music, but it is not suitable on the moral level.

　　Fu Jian, a lawyer of Henan Yulong Law Firm, said that in the online class, he publicly insulted others, derogated from others’ personality, and was suspected of infringing on the right of reputation, and was also suspected of violating the Law on Public Security Administration Punishment; If you distribute obscene pornographic videos, you are suspected of spreading obscene articles, and the criminal responsibility of the disseminator should be investigated according to law.

　　(The names in the text are all pseudonyms except Fu Jian and Zhao Zhanling.)

　　Chengdu Business Daily-Red Star Journalist Chen Qingyuan

I’ve seen too many suspense detective dramas, so I might as well change my taste. The public relations TV series "Emergency Public Relations" starring Huang Xiaoming, Cai Wenjing and Tan Zhuo is being broadcasted.

The drama, last romance, was premiered in 8 sets of CCTV prime files, and updated synchronously in Youku video. The plot adopted an unpopular theme "public relations" which is rare in China.

This "Emergency Public Relations" is based on real events, and strives to touch people’s hearts with truth, and narrates from topics such as family, workplace and love. Through the display of more than ten public relations events, this paper discusses social hot topics and shows the audience the real life of the crisis public relations industry.

This drama is the first urban drama starring Tan Zhuo, and it is also the cooperation between Tan Zhuo and director Hui Kaidong after Story of Yanxi Palace. It has attracted much attention before it was aired, but Tan Zhuo’s characters are not very pleasing this time.

Tan Zhuo’s new image positioning this time is Yuan Wei, a partner of a big law firm. She is independent, capable and elegant, and is regarded as a female elite in the workplace by others.

Just under this seemingly clever appearance, the love-hate entanglement between Tan Zhuo and her ex-boyfriend Lin Zhongshuo is also staged. Her attitude towards feelings and life has made them drift away.

Tan Zhuo and Lin Zhongshuo have been together for three years. On this day, Tan Zhuo suddenly walked into the house where they lived, took away his luggage, and claimed to go on a business trip abroad.

Unexpectedly, Yuan Wei’s business trip was just an excuse. Because her boyfriend Lin Zhongshuo didn’t work, she was angry and dissatisfied. She thought of a solution to break up, but they met unexpectedly at work.

Lin Zhongshuo graduated with a master’s degree in communication. He has worked as a reporter for 8 years in CBN, a famous domestic media group. He has had three sensational reports and is well-known in the industry.

It is precisely because of these sensational reports that Lin Zhongshuo has stayed away from the media industry, and he has never appeared in the public eye in these three years.

In the past three years with Yuan Wei, his life style of not working made his girlfriend worry about the uncertainty of the future. In Yuan Wei’s eyes, the two should grow up together, which is why Yuan did not choose to leave without saying goodbye and waved goodbye.

If the development of the incident ends here, then the new lawyer played by Tan Zhuo is quite capable and dashing as a city beauty, but her subsequent behavior greatly reduces her image.

After finding a new job in Lin Zhongshuo, she stood on the opposite side of her job and life.

A Chinese mother was treated unfairly when she took an international flight. The simple and rude way of flight attendants to deal with the problem was sent to the media by reporters, and the public opinion was biased in favor of this Chinese mother.

"Although public opinion is directed at you, you are not public figures. Even if you are scolded, it will not have an impact on your future life." Such a statement will not come from a conscientious legal worker.

As the legal adviser of this airline, Mr. Yuan is too objective and calm and impersonal. In the face of the bad words on the Internet, it is really unacceptable to choose to ignore the choice and let it go, and to put vulnerable individuals at the center of public opinion.

At present, after her boyfriend Lin Zhongshuo saved the day and kept his new job in a first-class public relations company in China, Lawyer Yuan chose to go back to the grass.

She first went back to the house where they lived together, trying to get Lin Zhongshuo to give her a step down and ease their relationship. This idea was seen through by Lin Zhongshuo, and his wish was unsuccessful.

She took the initiative to wait downstairs in Lin Zhongshuo’s company again and asked him to have dinner at night, but Lin Zhongshuo refused again.

Do we want to go further in our current relationship? This is the third attempt made by Yuan Wei. In the crowded lobby, Yuan Wei held Lin Zhongshuo’s hands and asked, and was rejected again.

Love is like this. When one party chooses to give up, it is impossible to talk about it. Yuan Wei is invincible in the workplace, but he still gets hurt in his feelings. This role is really not pleasing.

Since Tan Zhuo, Xú Zhēng, Zhou Yiwei and others co-starred in the film Dying to Survive in 2018, Tan Zhuo’s reputation in the film and television drama industry has soared.

After that, she participated in the costume court drama Story of Yanxi Palace. Although she played the role of Gao Guifei, she was overbearing, but under the role of Tan Zhuo, this role was well received.

Both Huang Xiaoming’s wife in The Fire Hero and the ordinary mother in Sheep Without A Shepherd make Tan Zhuo’s image shine.

There is no doubt that Tan Zhuo is a good actor, but the roles of good actors are not all so pleasing. This time, Emergency Public Relations is like this. Wen/Hua Su

Counties (cities, districts) Construction Bureau, municipal water supply and drainage company and all units directly under the Bureau:

The "Implementation Plan for the Construction of" Smart Site "in Lishui City" is hereby printed and distributed to you, please conscientiously implement it according to the actual work.

Lishui housing and urban construction bureau

December 9, 2019

(This piece is publicly released)

Issued by the Office of Lishui Housing and Urban-Rural Development Bureau on December 9, 2019 　

Implementation Plan of "Smart Site" Construction in Lishui City

In order to implement the Opinions of the General Office of the State Council on Promoting the Sustainable and Healthy Development of the Construction Industry (Guo Ban Fa [2017] No.19), the Notice of the Ministry of Housing and Urban-Rural Development on Printing and Distributing the Outline of the Informatization Development of the Construction Industry from 2016 to 2020 (Jian Zhi Han [2016] No.183) and the Notice of the Housing and Urban-Rural Development Department of Zhejiang Province on Accelerating the Construction of "Smart Sites" in the Province (Zhejiang Jian Zhi An Fa Effectively improve the efficiency of industry supervision and service, and improve the fine management level of the construction site in our city. Our bureau decided to immediately carry out the construction of smart sites, and formulated this implementation plan.

I. General requirements

Fully implement the requirements of high-quality development of the construction industry, take improving the engineering quality and safety level and building a harmonious and civilized industry environment as the main line, adhere to the problem-oriented and goal-oriented principles, and use the modern management concept of "wisdom+interconnection+collaboration" to build the subsystems of "smart site" according to local conditions in about two years, gradually realize the full coverage of the city’s "smart site" management system and connect with the province’s "smart site" management system.

Second, the basic situation

(1) Platform functions. Lishui Smart Work Site Platform includes video monitoring management, real-name registration system attendance management, environmental monitoring management, quality supervision and safety supervision, etc. Combined with the requirements of industry supervision functions, it gradually realizes functions such as quality, safety, dust prevention, project progress, personnel management, data statistical analysis and government supervision.

(2) Information collection. Smart site platform mainly collects basic information of enterprises and projects, video monitoring information, attendance information of real-name registration system, environmental monitoring information, quality and safety supervision information, etc., and realizes real-time early warning, task release and disposal based on the same platform, and later provides decision support through big data analysis services.

(3) management authority. Lishui Smart Site Platform is built and managed by the Municipal Construction Bureau in a unified way, and it is opened and applied to the relevant offices (stations) of the Municipal Construction Bureau, the housing construction departments of all districts (cities) and counties, and relevant enterprises and project departments according to the responsibilities and authorities, so as to realize the smart management of the city’s construction projects and improve the quality, safety and civilized construction control level of the city’s construction projects.

(4) Responsibilities of service providers. The network service provider is responsible for assisting the competent business department in daily maintenance of the system platform, network access, system training and site equipment compliance acceptance service. The construction unit and equipment service provider are responsible for the installation and daily maintenance of site equipment, that is, who installs, manages and is responsible.

Third, the construction content

(A) video surveillance

1. Scope of implementation

Since December 10, 2019, the following construction projects must be equipped with an online video surveillance system and connected to the platform:

(1) Projects with a newly started construction area of 5,000 square meters or more after December 10, 2019, including new construction, renovation and expansion of houses; Municipal infrastructure projects with a project cost of 20 million yuan or more.

(2) Construction projects under construction with a construction area of 5,000 square meters or more that have not been accepted by the main branch project before December 10, 2019; Municipal infrastructure projects under construction with a project cost of 20 million yuan or more and a remaining construction period of 6 months or more.

(3) The construction projects listed in Lishui City’s standardized construction site creation plan for building safety and civilized construction, including those newly built or whose main branch projects have not been accepted before December 1.

Meet the above conditions, it is a special project or other special circumstances, the project is located in the construction department for examination and approval, you can not install online video monitoring system.

2. Installation requirements

(1) The number of video monitoring points installed. Housing construction project construction area of less than 20 thousand square meters, not less than 1 ball machine and 3 bolt machines; Housing construction project construction area of 20 thousand square meters and less than 50 thousand square meters, not less than 1 ball machine and 4 bolt machines; For every 50,000 square meters increase in construction area, it is necessary to add another ball machine monitoring point; For projects with complex surrounding environment or large scale, the number of video monitoring points should be increased according to the actual needs of the project, and the specific requirements should be determined by the construction administrative department where the project is located.

(2) Installation position of video monitoring point. The arrangement and installation of video monitoring points should be determined according to the actual situation of the construction site. The main installation positions are as follows: the highest point of the construction site (the installation position of the ball machine), the entrance and exit of the construction site, the vehicle washing pool, the processing area, major hazard sources and other parts. If there is a living area, at least one gun must be installed in the living area, and each entrance with multiple entrances and exits in the construction site should be equipped with a gun monitoring point. The installation position should be the most reasonable and favorable position that can reflect the construction situation of the project. Ensure that the construction status of personnel, major hazard sources and engineering subjects at the entrance and exit of the whole project can be displayed. The installation height should be considered to meet the needs of the whole construction process and reflect the construction status of the main places as much as possible. The monitoring points should be installed at locations that do not need to be moved during construction as far as possible to avoid repeated demolition and reinstallation.

(3) Technical standards and access requirements of video monitoring system. See Annex 1 for the technical standards of video surveillance system. Only qualified equipment can access the platform. See Annex 2 for the interface protocol of video monitoring platform. Monitoring equipment meeting the requirements of technical standards should be adopted in each construction site, and the Municipal Construction Bureau should be contacted for testing and access. Units that have completed the construction in advance should upgrade all kinds of equipment that do not meet this standard to ensure that they can be integrated with the platform.

(2) real-name registration system attendance

1. Scope of implementation

All newly started projects after December 10, 2019 will be connected, and the projects that have started, special projects or other special circumstances are the same as video surveillance requirements.

2. Attendance object

Main management personnel and construction workers of construction and supervision units.

3. real-name registration system attendance equipment installation requirements

(1) Installation quantity and location. The quantity of equipment shall be purchased according to the actual demand of the construction site, and the actual attendance needs shall be met. The equipment shall be installed at the main entrance and exit positions. In order to ensure the equipment identification effect, the installation position shall avoid east-west orientation as far as possible.

(2) real-name registration system attendance equipment technical standards and access requirements. See Annex 3 for the technical standard of attendance equipment in real-name registration system. Only qualified equipment can access the platform. See Annex 4 for the interface agreement of real-name registration system attendance equipment platform. real-name registration system attendance equipment meeting the requirements of technical standards should be adopted in each construction site, and contact the Municipal Construction Bureau for testing and access. Units that have completed the construction in advance should upgrade all kinds of equipment that do not meet this standard to ensure that they can be integrated with the platform.

(3) Environmental monitoring

1. Scope of implementation

(1) Newly started projects covering an area of 5,000 square meters or more after December 10, 2019, including new construction, renovation and expansion of housing construction projects; Municipal infrastructure projects with a project cost of 20 million yuan or more.

(2) Construction projects under construction with a building area of 5,000 square meters or more that have not been accepted by the main branch project before December 10, 2019; Municipal infrastructure projects under construction with a project cost of 20 million yuan or more and a remaining construction period of 6 months or more.

(3) The construction projects listed in Lishui City’s standardized construction site creation plan for building safety and civilized construction, including those newly built or whose main branch projects have not been accepted before December 10th.

Meet the above conditions, it is a special project or other special circumstances, the project is located in the construction (construction) department in charge of examination and approval, you can not install online environmental monitoring system.

2. Collecting parameters

PM10, PM2.5, noise, temperature, humidity, wind power, wind direction and wind speed.

3. Installation requirements of environmental monitoring equipment

(1) Installation quantity requirements. The quantity of equipment shall be purchased according to the actual demand of the construction site, and if the area is within 50,000 square meters, at least one inspection point shall be installed; For every 50,000 square meters of floor space, one more monitoring point will be added. Meet the requirements of municipal infrastructure projects each bid set at least 1 monitoring point. Installed at the main entrance or exit or around the foundation pit.

(2) Installation position requirements. The monitoring equipment shall be installed within the enclosure of the construction site and can directly monitor the main construction area on the site. The on-site spraying system should avoid the on-line monitoring facilities for dust, and should not interfere with the normal monitoring of the monitoring facilities. If one monitoring point is set, it should be set at the main entrance and exit of construction vehicles; If two or more monitoring points are set, at least one of them should be set at the main entrance and exit, and the rest should be set at the field boundary closest to the surrounding sensitive points. When it is adjacent to other construction projects, monitoring points should be avoided at the adjacent boundary.

(3) Technical standards and access requirements of environmental monitoring equipment. See Annex 5 for the technical standards of environmental monitoring equipment. Only the equipment that meets the requirements can access the platform. Refer to Annex 6 for the interface agreement of environmental monitoring platform. Monitoring equipment meeting the requirements of technical standards should be adopted in each construction site, and contact the Municipal Construction Bureau for testing and access. Units that have completed the construction in advance should upgrade all kinds of equipment that do not meet this standard to ensure that they can be integrated with the platform.

IV. Procedures

The installation, use and removal of smart site equipment shall be handled according to the following procedures:

(1) Determine the installation scheme. Network operation service providers go to the construction site for survey, and jointly determine the number of equipment points, installation locations, installation plans, etc. with construction, supervision and construction units; The construction unit shall complete the production of the equipment installation scheme and point layout of the smart construction site in the construction site, fill in the Notice Form for Equipment Installation of Smart Construction Site in Lishui City (Annex 7), and report it to the construction engineering quality and safety supervision institution where the project is located for the record. 　

(2) Installation and use. With the cooperation of the construction unit, the supervision unit and the construction unit, the network operation service provider installed the special network for the smart site. After the construction unit passed the acceptance, the smart site system was officially put into use. Within one month after the official start of the project, at least two video monitoring points (vehicle washing pool and real-name registration system attendance machine), environmental monitoring equipment and real-name registration system attendance equipment must be installed, and other smart site equipment should be installed in time according to the construction progress.

(3) Modification of the system scheme. No unit or individual is allowed to modify the reviewed smart site plan and smart site equipment layout plan without authorization. If it is really necessary to modify, the construction unit shall apply, and the modification can only be made after the network operation service provider, supervision unit and construction unit audit and report to the construction administrative department where the project is located for approval.

(4) Demolition and relocation. Without the consent of the construction administrative department where the project is located, the construction unit shall not dismantle or move the smart site equipment. If it is necessary to dismantle or move the equipment, the construction unit shall go through the formalities at the construction administrative department where the project is located three working days in advance, and fill in the Notice Form for Equipment Demolition (Relocation) of Lishui Building Engineering Smart Site (Annex 8). With the Notice Form of Equipment Removal (Relocation) of Lishui Smart Construction Site, the network operation service provider will remove or move the dedicated network of smart construction site, and the construction unit shall not remove or move the smart construction site equipment without authorization.

V. Supervision and management

(1) Local construction authorities should regard smart sites as an important starting point for quality and safety supervision, strictly implement them in accordance with the provisions of the implementation measures, and urge those sites that fail to install the smart site system on time, refuse to install the smart site system, and fail to ensure that the smart site system is in good working condition to be rectified in place, so as to promote the smooth implementation of smart sites. Local construction authorities shall supervise the construction sites under construction in real time through the smart site system, and keep account records.

(2) For the construction projects that have started before the implementation of this notice and need to install smart site systems, the equipment installation and system access of all smart site systems should be completed before December 31, 2019.

(III) The construction of smart site is included in the "one-vote veto" of creating a standardized construction site for building safety and civilized construction in Lishui City. In accordance with the requirements of this notice, a site that fails to install or refuses to install the smart site system on time and cannot guarantee that the smart site system is in good working condition may not participate in the standardized construction site for building safety and civilized construction in Lishui City in principle.

(four) local construction authorities shall, within 3 working days after receiving the application for modification or removal of the smart site system, review and reply to the applicant.

(five) local construction departments should complete the construction of local smart site sub-centers before June 30, 2020, and can formulate implementation rules according to this notice.

VI. Maintenance Management

(1) Network operation service providers and equipment service providers that provide smart site system services must ensure the normal operation of smart site systems, diagnose equipment failures in real time and immediately deal with them, and regularly send people to the construction site for maintenance. 　

(2) The construction unit shall assign a special person to be responsible for the management of smart site systems and equipment, and complete the work of scheme formulation, contract signing and equipment acceptance, and check and make records every day. If abnormal conditions are found, it is necessary to find out the reasons and notify network operation service providers and equipment service providers in time, take effective measures to ensure the safety of facilities and lines in smart construction sites, and actively do a good job in maintaining facilities and lines. If it is found that the monitoring equipment of the smart site is intentionally damaged, the competent construction department where the project is located shall immediately order it to be repaired immediately.

(3) If the smart site system fails, all relevant units should carry out maintenance as soon as possible according to the contract, and in principle, the repair should be completed within 24 hours after receiving the report.

(4) In order to ensure the effective implementation of the smart site, the expenses of online video monitoring system such as leasing, installation, debugging, maintenance and network leasing are included in the expenses of safety protection and civilized construction measures of construction projects, and the funds are special.

(5) Local construction (construction industry) authorities, construction engineering quality and safety supervision institutions, construction units, construction units and supervision units should use the smart site system to realize remote dynamic supervision and management of the construction site. The login website, user account number, password and usage of the smart site system are provided by Lishui Housing and Urban-Rural Construction Planning Bureau and network service providers.

Li Jianfa [2019] No.225 Annex. doc

This article comes from WeChat WeChat official account:Eight o’clock news (id: healthinsight), author: ChenGuangjing, original title: "Multinational pharmaceutical companies in China for 40 years: from super-national treatment to ordinary players", the first picture comes from: vision china

For more than 40 years, multinational pharmaceutical companies have attracted countless amounts of money by virtue of China’s policy bonus and the environment where they have little power to compete with it.

In the running-in of multinational pharmaceutical companies and China’s characteristic market economy for more than 40 years, it has gone through the process from the initial foreign monks who can recite scriptures, to disenchantment, to checks and balances, and then to adjustment and discovery of new modes of getting along.

Objectively speaking, multinational pharmaceutical companies have contributed to the development of China’s pharmaceutical industry, and they have participated in creating the second largest pharmaceutical consumption market in the world.

However, they have enjoyed "super-national treatment" in China for a long time, including independent pricing and tax concessions.It has also brought many problems, including the intensification of overcapacity at the industrial end; The drug price in the public remains high, and patients can’t afford drugs.With the rise of local pharmaceutical companies, it is almost inevitable that their aura will recede.

The rise and fall of multinational pharmaceutical companies in China perfectly fits the development course of the whole pharmaceutical industry in China. So,The road taken by multinational pharmaceutical companies in China is almost a history of the development and policy changes of China’s pharmaceutical industry.

First, the first encounter: the introduction of more than just funds.

In 1978, China Pharmaceutical gross industrial output value was 7.3 billion yuan, which may not even be comparable to the revenue of a pharmaceutical company Pfizer-in the 1970s, Pfizer’s annual revenue was 1 billion dollars.

At that time, the pharmaceutical industry in China was in the stage of stumbling, and competitive domestic enterprises did not exist. There were only more than 500 kinds of drugs that hospitals could use daily.

Later, Yangzijiang Pharmaceutical, which claimed to have an annual income of 100 billion yuan, was still an unknown small factory in the town; Lianyungang Pharmaceutical, the predecessor of Hengrui, is still making hemostatic and disinfectant, and Sun Piaoyang, the technician who changed its fate, was not assigned here until four years later.

At first, foreign pharmaceutical companies were introduced, not for new drugs, but to introduce a large infusion model production line that meets the standards and can be sold all over the world.

The first foreign pharmaceutical company to enter China was Otsuka Pharmaceutical Co., Ltd.. It was signed in 1980 and put into production in 1984. By the end of 1980s, Otsuka, China had been able to produce 8 kinds of injections, which were supplied to big hospitals in Beijing, Shanghai, Tianjin and other cities, and also sold to Japan, with a double-digit increase in production capacity, sales volume and profit.

Otsuka, China, made a good start, and a large number of multinational pharmaceutical companies began to tentatively enter China.What they value has also developed from China’s industrial policy, preferential tax, low cost and labor to China’s huge market.

According to Medicine World, China joined the World Trade Organization as of December 2001.（WTO）The number of foreign-funded pharmaceutical enterprises in China has reached about 1790. The top 20 pharmaceutical companies in the world have invested and set up factories in China. In terms of market share, these enterprises account for half of the pharmaceutical market in China.

More important than market share,From production to sales, these foreign pharmaceutical companies have almost reconstructed the pharmaceutical industry in China.

Foreign-funded pharmaceutical companies not only brought more funds, mature technologies, brand-new concepts and management models, and more available new drugs to the pharmaceutical industry in China, but also brought the mainstream sales model in the pharmaceutical field at that time-academic marketing, and a new profession-pharmaceutical representative.

By 2016, China has more than 3 million medical representatives, supporting a huge sales system with a scale of 2 trillion drugs, serving 12,000 public hospitals in China.

In 1980s in China, under the strict planned economy system, pharmaceutical companies completed their production as planned, and then they were purchased by local pharmaceutical companies for unified deployment.

Pharmaceutical companies do not need to face the terminal market directly, and no one knows how to sell drugs in the modern pharmaceutical industry.

The pharmaceutical industry in Europe and America, after experiencing the rapid expansion and fierce competition after World War II, has long understood the key to the commercialization of medicine-doctors with prescription rights are the real customers of pharmaceutical companies, and the sales model for doctors is the truly effective modern pharmaceutical sales model.

Established in 1985, Xi ‘an Jansen introduced Jansen’s staff training mechanism and built the first pharmaceutical sales team in China, which is known as the "Whampoa Military Academy" in China’s pharmaceutical industry.(See:The 30-year ups and downs of China medical representatives.).

Most of these first-generation medical representatives employed by foreign-funded pharmaceutical companies have professional backgrounds, have access to first-hand scientific research materials, and were respected by doctors in the early days.

However, the situation changed quickly, and some domestic pharmaceutical companies quickly grasped the essence of pharmaceutical marketing and alienated it, resulting in sales with gold and kickbacks-hidden transactions.(doctor’s rebate+public relations rent-seeking)The cost once soared to 60% of the drug price.(See:China Medicine Changed the Past.).

Under the pressure of sales, foreign pharmaceutical companies have also begun to adopt a more subtle way of bribing doctors, as foreign media mentioned in a report in 2013: "Persuade with cash, gifts, vacations and other benefits.(medical staff)Write more prescriptions. "

All these will lay the foundation for a huge bribery case that is almost comparable to Waterloo, China, a multinational pharmaceutical company.

Second, localization: the rapid development of golden decade

In 2001, China officially joined the WTO.(World Trade Organization)China’s reform and opening up has deepened its integration with the world economic system.

Under the expectation of opening up to China and the expectation of the vast market, multinational pharmaceutical companies began to "settle down" frequently.

According to the later analysis of the industry, this process is to compete for the market, but also a confession meeting to show confidence in the China market. The giants scrambled to present "warlords" by investing in the establishment of R&D centers and factories.

After January 2002, more than 10 giants such as Novo Nordisk, AstraZeneca, Roche, Takeda, Pfizer, GSK and AbbVie also set up R&D centers in China. Lilly Asia Venture Capital Fund has also targeted the China market, with an initial investment of US$ 10 million, and plans to invest US$ 100 million in drug research and development capacity in China within five years.

According to industry statistics, by 2016, these multinational pharmaceutical companies have spent more than 8 billion yuan just to set up research centers in China.

Different from the new construction in the field of research and development, the "falling" in the field of production and sales is more like a game of "greedy snake".

In 2000, Pfizer won the largest acquisition in the history of the pharmaceutical industry with a sum of 90 billion US dollars, acquired its research and development company Warner-Lambert, and put Atorvastatin.(trade name Lipitor)In the pocket, thus surpassing Merck, the former overlord, and ranking first in the pharmaceutical revenue list. This also triggered a wave of mergers and acquisitions

This "snake-eating" game also extended to China. On July 2, 2008, after nearly two years’ efforts, Bayer finally completed the necessary regulatory approval and bought Dongsheng Technology’s "White Plus Black" and other anti-cold and cough products for 1.072 billion yuan.This also opened the prelude for multinational pharmaceutical companies to merge with China pharmaceutical companies.

Second year(2009)In the first half of the year alone, at least seven multinational giants announced the expansion of factories and production lines or the news of mergers and acquisitions and joint ventures. In the 2010s, the momentum became stronger and stronger. Merck, Pfizer, Sanofi, GlaxoSmithKline, Novartis, etc. joined in one after another. Among them, Sanofi bought the local pharmaceutical company Meihua Sunstone Group and bought a high price of over 520 million US dollars, which was the largest merger in China at that time.

Correspondingly, during the critical period of attracting investment in China, multinational pharmaceutical companies almost enjoyed the "super-national treatment" in policy.

Among them, mainly including tax incentives; Independent pricing, filing system, etc. Among all these "treatments", the most "useful" is the right of independent pricing.

Before the government pricing of most drugs was officially cancelled in 2015, only exclusive varieties could be priced independently. However, multinational pharmaceutical companies often introduce patented drugs into China, which can set higher prices.

This makes these drugs form a "scissors gap" with domestic drugs.

During this period, the scale of China pharmaceutical market has been greatly expanded. The output value of the top 100 pharmaceutical enterprises exceeds 300 billion yuan, but the concentration is less than 35%. The enterprises are "small, scattered and chaotic", and the product quality cannot be compared with imported drugs, let alone replaced. In order to compete for the market, a unique marketing model with gold sales was formed, and "emphasizing sales and neglecting research and development" began to become the mainstream of market competition during that time.

The market mechanism fails in the medical field, and the higher the drug price, the more room for operation. This is even more powerful for multinational pharmaceutical companies.Imported drugs occupy the commanding heights of the pharmaceutical market. And this advantage is more and more obvious after the patented drugs have passed the protection period.

Before and after 2006, the former director of National Medical Products Administration, Zheng Xiaoyu, was sentenced to death. As a warning, the whole drug supervision system overcompensated the behavior of rent-seeking and approving homogenized "new drugs". The drug review and approval in China was tightened rapidly, and the approval speed of domestic generic drugs was slow, resulting in a serious backlog.

In the pharmaceutical market of China, the price of drugs that have passed the patent period has started to remain high, and the gap with domestic generic drugs continues to widen.

According to some data, by 2013, the ratio of the original research drug of ceftriaxone to the retail price of generic drugs has expanded from the previous 6.25: 1 to 9.35: 1. One product and two regulations in the hospital have also become an imported product and a domestic medicine.

Many "life-saving drugs" with high technical barriers even have the highest situation in the world. For example, Gleevec of Novartis entered the mainland market of China in 2002, and the price per box was as high as 25,800 yuan. Since then, the price has remained basically stable, and by 2014 it has been much higher than 17,000 yuan in Hong Kong, China and 13,600 yuan in the United States.

Under the disparity of strength and weakness, multinational pharmaceutical companies have gradually entered the golden age of "lying down to make money" in China.

In order to further expand their advantages, multinational pharmaceutical companies also strive to expand their sales teams.

According to a paper published by Yale Law School scholars in 2014, the top 10 pharmaceutical companies in the world employ about 25,000 sales teams in China. According to IMS statistics, multinational giants such as Pfizer, Bayer and AstraZeneca have more than 2,000 first-line medical representatives, and there is a trend of further expansion.

According to statistics, the pharmaceutical market in China achieved a compound annual growth of 25% in the decade after 2000, and the income of multinational pharmaceutical companies also rocketed. AstraZeneca, for example, has built a factory in China for four years, and its sales revenue has exceeded 1 billion yuan, which is called the "dream team" of multinational pharmaceutical companies. Although other pharmaceutical companies do not have more data to prove it, they can also see clues from the grand annual meeting.

After Pfizer acquired Wyeth in 2010, an annual meeting in Dongguan, Guangdong Province cost 30 million yuan and more than 5,000 employees participated. At that time, it was called the "annual meeting of the best company". Previously, Bayer led more than 1,600 employees to carnival in Jeju Island, South Korea for 6 days, and the industry analysis cost will not be less than 30 million yuan.For a long time, the annual meeting of multinational pharmaceutical companies in China is an event that attracts the attention of the industry.

It was a prosperous time for multinational giants to develop rapidly. However, in the carnival, no one noticed the hidden worries that might make their "aura" recede.

Third, the blow: loss of supranational status

In 2013, GSK was fined a sky-high price for bribery in China, several senior executives were sentenced and one foreign executive was deported.

For a long time before GSK bribery case, multinational pharmaceutical companies were often regarded as synonymous with professionalism and compliance because of their "halo" in China market.

Until 2004, foreign media published an article exposing the "kickback shady" of pharmaceutical giants.People suddenly discovered that some so-called "standards", "rules" and "international practices", which people take for granted as reasonable behaviors, such as traveling and lecture fees, also have the risk of interest transfer.

However, in the process of law enforcement since then, due to hidden methods and insufficient legislation in China, regulators have not made a clear statement on these behaviors.

After GSK’s bribery case in China was exposed, people suddenly understood that the localization of multinational pharmaceutical companies has extended to the field of sales with gold, and the amount is so huge.

According to public information: GSK(China)In order to increase sales, a large number of salespeople were recruited and paid bribes to medical staff in medical institutions all over the country. Travel expenses, lecture fees, organizing tours, etc. are all ways to expand the use of drugs or expand their use. Only after 2007, GSK, like more than 700 travel agencies and consulting companies, transferred 3 billion yuan, which was suspected to be used for "illegal fund disposal".

Since the GSK case, people have clearly realized that,China’s regulators are ready to "shoot".

In fact, multinational pharmaceutical companies entered the China market in the form of joint ventures from the beginning. Their technology is often not the latest technology. It is mentioned in Mainstream-Wisdom of the Leaders of Pharmaceutical Companies in China that the overseas direct investment theory of developed countries clearly mentions that the core technology will remain in the headquarters, and the second-rate technology and production line will flow overseas. Inadequate management, and multinational pharmaceutical companies create book losses and evade taxes by making high prices of overseas raw materials.

During this period, scholars in China also realized that we can’t catch up with the international level by introducing foreign capital to build tertiary industry.

However, in the early days of reform and opening up, China’s technology was too weak, and these mature technologies can meet the demand to a certain extent.

However, in the subsequent development, local pharmaceutical companies in China are also rising rapidly.

Today, even the world’s leading PD-1 inhibitor has become the object of research and development. According to Baiaotai’s announcement, after Bristol-Myers Squibb and Merck launched PD-1 in 2014, 85 of the 154 PD-1 in the world were developed or jointly developed by China enterprises.

Since 2018, only five domestic PD-1s in China have been approved for listing.

Under the pressure of domestic drug competition, the imported PD-1-O and K drugs, which initially cost 1 million yuan to be listed in the United States, were given the lowest price in the world as soon as they entered China. After several rounds of price wars, the annual cost continued to drop sharply.

Especially after the national medical insurance negotiations, under the offensive of price reduction of domestic drugs, although the above two imported drugs were not successfully negotiated, the annual expenses were also reduced from more than 300,000 yuan and more than 200,000 yuan to more than 100,000 yuan. The domestic PD-1 can even reduce the personal out-of-pocket expenses to 10,000 yuan.

The state-led "Major New Drug Creation" project was also launched in 2008. By 2019, there were 139 new drug certificates, 44 of which were Class I new drugs. These drugs are all "chips" in the game of medical insurance negotiation and forced price reduction of imported drugs.

Before the GSK bribery case was investigated, "domestic Iressa" Ectinib went on the market. This small molecule targeted drug with completely independent intellectual property rights in China broke the monopoly position of European and American pharmaceutical companies. In the first national negotiation in 2015, Iressa was forced to reduce the price by 55%, and the average monthly cost dropped from 12,000 yuan to about 5,500 yuan. This is not only the preface of domestic substitution of imported drugs, but also gives the competent authorities the confidence to severely punish GSK.

Nowadays, innovation has become the common choice of more and more head pharmaceutical companies. Statistics show that the total value of China’s pharmaceutical industry has been close to 3 trillion yuan by 2017. In 2019, the income from the main business of the top 100 enterprises reached 929.64 billion yuan, with a growth rate of over 10%. The average R&D cost is more than 550 million yuan.

According to Wind data, the R&D investment of A-share pharmaceutical enterprises in China was less than 10 billion yuan in 2011, and it has exceeded 50 billion yuan by 2019. Judging from the annual reports, in 2020, there will be as many as 14 R&D investments in China exceeding 1 billion yuan; The research and development of more than 40 pharmaceutical companies accounts for more than 10%.

China is increasingly emboldened to reduce the price of imported drugs. With more and more domestic innovative drugs on the market and generic drugs passing the consistency evaluation, a subversive reform is gradually taking shape.

The rules of the game have changed, and multinational pharmaceutical companies have changed from the role of "wrestling" with policy makers to ordinary players, who can only comply with the rules and compete fairly with local pharmaceutical companies.

Fourth, the Great Retreat: How many people want to go back ten years ago?

In 2017, leaving the shut-down Shanghai Lilly China R&D Center not only announced the end of an era, but also seemed to push down the first domino of foreign companies’ assets withdrawing from China.

Then Novartis dissolved the biopharmaceutical research and development team in China, and the early research and development of antibiotics and antiviral drugs was stopped, and 140 people were abolished; GSK China R&D Center was abolished, and the project under research was transferred to American research center; Novo Nordisk China R&D Center layoffs; AstraZeneca China preclinical research business divested …

Dominos continue to overwhelm more business.

In 2019, Lilly sold the rights of antibiotic varieties Xikelao and Jingkexin in Chinese mainland, as well as the production plant of Xikelao in Suzhou.

Pfizer also packaged mature products such as Lipitor and Luohuoxi into Pfizer Puqiang and eventually merged them with generic drug giant Mylan.

Since then, GSK and Novartis have also sold their factories in China. Boehringer Ingelheim stripped off the promotion of Aiquanle, Kebite, Silihua and Sihehua; Mengdi Pharmaceuticals is simply selling its business unit in China.

In 2021, more and more heavy product lines in the past were "killed with tears".

Then, a batch of drugs began to withdraw from the China market. Just three months ago.(May 24)Among the 283 cancelled approval drugs announced by National Medical Products Administration, Weijianle of AbbVie is included.(Obipali tablets), Yi Chery(Dasebvir Sodium Tablets), Li Luo of Johnson & Johnson.(Procarbidol Succinate Tablets)Cape orchid with excellent time ratio(levetiracetam tablets), Novi of Merck.(Sigliptin Phosphate).

Many of these products, such as Merck’s hypoglycemic drug Genevix, are on the track with annual sales of several billion yuan, and now it is a mixed feeling to leave.As for the strategic deployment of multinational pharmaceutical companies, some investors even ridiculed that this is the "Dunkirk" of the pharmaceutical industry.

In the past four years, the state organized the centralized procurement of medical equipment, which set off a huge wave in the pharmaceutical market in China, which was called "tsunami". Although only 218 varieties are involved at present, the market scale is 220 billion yuan, but its foreseeable influence has made people who are used to the traditional marketing to conquer the world feel insecure.

There is no room for further clinical promotion, regardless of whether the bid is won or not, because the price is cut at the waist and ankle. The traditional marketing model is facing unprecedented challenges. It is difficult for multinational pharmaceutical companies to win the bid in order to maintain global prices.

In the field of innovative drug research and development, the giants have also encountered close-knit struggles from local enterprises. The once unattainable PD-1/PD-L1 was dragged into the Red Sea by China pharmaceutical companies. From the annual cost of millions of yuan to the minimum of less than 20 thousand yuan.

Mature products are surrounded by generic drugs, new products are facing price cuts in medical insurance negotiations and rapid attacks from competitors. Multinational pharmaceutical companies are in a crisis of being besieged on all sides.

In order to maintain their advantages and seek new growth points, in addition to divesting "non-core business", the adjustment and breakthrough of multinational pharmaceutical companies have never stopped.

In January 2019, the distance from cardiovascular heavy drugs was "determinable"(Chemical name: rosuvastatin)Just two months after losing the bid in the 4+7 pilot project, AstraZeneca, which is known as the "dream team", threw a heavy news: it has obtained the exclusive promotion right of Xuezhikang in Chinese mainland from the Green Leaf Group.

Multinational pharmaceutical companies sell proprietary Chinese medicines, which breaks through the inherent cognition of the industry. What breaks the industry cognition even more is that it has also started CSO.(Contract Sales Organization), "big package business".

A year later, AstraZeneca accepted the exclusive promotion right of a medical-grade home twelve-lead ECG instrument in China. According to the medical economic news, the company will also package 100 products-50 domestic or imported agent products and 50 diagnostic equipment products.

The sales cooperation between domestic pharmaceutical companies and multinational pharmaceutical companies is getting closer and closer, and the industry is beginning to be surprised by this treatment. Even Pfizer, once a "big pharmaceutical factory in the universe", has come to an end.

Not long ago, Cao Junyang, vice president and chief medical officer of Pfizer China, also revealed in an exclusive interview with the medical profession that apart from speeding up the introduction of self-developed products into China, Pfizer will also cooperate with local enterprises or multinational enterprises to give full play to its "leading commercialization advantage in the pharmaceutical field in China".

Simply understand, that is, to give play to its advantages in the sales field.

With the accumulation of sales teams in the past decades, the choice of multinational pharmaceutical companies is unexpected, but it is reasonable.

With the aging and high incidence of cancer, the pharmaceutical market in China has maintained a high-speed growth all the year round. Foresight Industry Research Institute predicts that by 2025, with its growth rate of 14% to 17%, it will exceed 5 trillion yuan.

Such a "big cake" can’t be eaten without sincerity, and multinational pharmaceutical companies are also trying their best.

From 1980 to 2021, the scale of the pharmaceutical market in China increased from less than 8 billion yuan to nearly 3 trillion yuan.

Can multinational pharmaceutical companies that have lost their "aura" subvert their profit model for 40 years in a brand-new pattern and rules and find a new way in this trillion-dollar market?

References:

Introduction, for digestion and absorption-Notes on an interview with China Otsuka Pharmaceutical Co., Ltd., Cong Yu.

"Creating a New Management Situation by Producing World-class Products —— An Interview with China Otsuka Pharmaceutical Co., Ltd.", Zhang Zhitao.

Mainstream-the Wisdom of China Pharmaceutical Leaders, Tao Jianhong, Tan Yong.

The Impact of Foreign Capital Utilization on China’s Pharmaceutical Industry, Liu Xue, Chen Wenxuan, etc.

The investment mind of multinational pharmaceutical companies has changed, He Rong.

This article comes from WeChat WeChat official account:Eight o’clock news (id: healthinsight), Author: Chen Guangjing

　　CCTV News:Precision manufacturing is the main pillar of Japanese manufacturing, and it is regarded as Japan’s "national business card". However, last year, after Kobe Steel Works was exposed to fraud scandals and continued to ferment, more and more leading Japanese manufacturing enterprises encountered the "quality gate", and Japanese manufacturing was falling from the "altar" to the "quagmire".

　　"The problem of making Japanese manufacturers lose their sense of trust has developed into a criminal case." Kyodo News reported on the 5th that the Special Search Department and the Metropolitan Police Department of the Tokyo District Prosecutor’s Office of Japan conducted a home invasion search on five locations in Tokyo and Kobe office buildings of Kobe Steel Works and three factories on the grounds of suspected violation of the Anti-Unfair Competition Law that day. The report stressed that although the company voluntarily submitted some information, considering its decades-long data fraud, it decided to "carry out compulsory search".

　　Established in 1905, Kobe Steel Works is the third largest steel producer in Japan, the top supplier of aluminum products and copper products in Japan and one of the top 500 enterprises in the world. Japanese Prime Minister Shinzo Abe worked in Kobe Steel Works before he entered the political arena. He also revisited his hometown twice as prime minister and wrote an inscription praising his technology and quality.

　　However, in October 2017, many factories in Kobe Steel Works were exposed to long-term tampering with the factory inspection data such as the strength and size of aluminum and copper products, and then it was exposed that the parameters of iron powder products were falsified, which led to the questioning of its entire line of products.

　　The Chinese official website of Kobe Steel Works shows that "the wire rod for automobile valve springs is used by one in every two cars in the world", "the aluminum sheet for automobiles accounts for 50% of the Japanese market" and "the aluminum profile for railway vehicles accounts for the highest share of the Japanese market".　

　 　 　 　 　Therefore, the "suspected fraud" of Kobe Steel Works can be described as "pulling the whole body", and about 200 Japanese companies have been affected. Toyota, Nissan, Honda, Mitsubishi, Subaru, Mazda, Suzuki and other Japanese car companies have confirmed the use of the problem parts, and the affected parts are mainly engine covers and doors. The Shinkansen train of Donghai Railway Company and the first Japanese-made jet regional aircraft MRJ under development were all found to have used aluminum products that did not meet Japanese industrial specifications.

　

　　Guangxi Baziling Great Wall VS Beijing Badaling Great Wall

　　Built in imitation of the Badaling Great Wall in Beijing, the Baziling Great Wall in Luchuan County, Yulin City, Guangxi Province quickly became popular and became a popular "punch-in" point for local people. On the 23rd, the reporter went to Luchuan County to visit this building which was called the Guangxi version of the "Great Wall" by netizens.

　　On November 23rd, aerial photography was taken of the "Baziling Great Wall" in Guilinggu rural tourist area, Luchuan County, Guangxi. Photo by Chen Guanyan

　　Starting from Luchuan County, it takes about an hour to drive to the Guiling Valley rural tourist area located in Baziling, Gao Qing Village, Shapo Town, Luchuan County, Yulin City. The gate of the scenic spot is a "Little Great Wall" built after the Badaling Great Wall, and the words "The Great Wall for Sightseeing in the Guling Valley" are impressive.

　　On November 23, tourists took photos at the "Baziling Great Wall" in the rural tourist area of Guilinggu, Luchuan County, Guangxi. Photo by Chen Guanyan

　　Climb up the stone steps and come to the highest "beacon tower" of the "Baziling Great Wall", surrounded by mountains and sometimes misty clouds. From afar, you can see Xiexianzhang, the highest mountain in Luchuan County. As can be seen from the aerial picture, the "Baziling Great Wall" is shaped like a "eight" and extends to both sides.

　　On November 23rd, aerial photography was taken of the "Baziling Great Wall" in Guilinggu rural tourist area, Luchuan County, Guangxi. Photo by Chen Guanyan

　　It was named "Baziling Great Wall" because it was built in Baziling.

　　Ruan Guansheng, the person in charge of Guilinggu Rural Tourism Zone, introduced that the "Baziling Great Wall" project was built under the guidance of Luchuan County Party Committee and Government, and efforts were made to create a new bright spot in the combination of industrial poverty alleviation and rural tourism. The project is planned to build 2000 meters. At present, the first phase of the project has been completed 450 meters, and the trial operation began during the National Day holiday this year.

　　Ruan Guansheng introduced that the "Baziling Great Wall" is actually a sightseeing corridor in the tourist area, named after it was built on the local Baziling. Before the project construction, it has been approved by Luchuan County Environmental Protection Bureau.

　　Ruan Guansheng said that the "Baziling Great Wall" was built on the ridge, which was originally a forest fire zone with sparse vegetation. Mountain fires often occur in the local area. After the "Baziling Great Wall" is repaired, Gao Qing Village and Bei ‘an Village on both sides will be separated to play the role of isolation and fire prevention. Considering the problem of environmental protection, the cement sand used in the construction of the "Baziling Great Wall" is all carried up the mountain by horses.

　　On November 23, tourists took photos at the "Baziling Great Wall" in the rural tourist area of Guilinggu, Luchuan County, Guangxi. Photo by Chen Guanyan

　　Quickly became popular and controversial.

　　Ruan Guansheng introduced that the "Baziling Great Wall" began trial operation during the National Day holiday this year, which attracted many tourists to visit and visit, and the small holiday received about 35,000 tourists. "At that time, tourists were full and meals were in short supply."

　　The reporter noticed that on the network platform, the topic of "high imitation of the Great Wall" has attracted the attention of many netizens. Netizens have different views on the "high imitation of the Great Wall". Some people think it is a "knockoff", which has no historical connotation and is meaningless. Some people think that it is good to climb the Great Wall in Guangxi.

　　On the 23rd, there was an endless stream of tourists visiting the "Baziling Sightseeing Great Wall". People have taken photos at the "Haohanpo" of the "Baziling Great Wall".

　　On November 23, tourists took photos at the "Baziling Great Wall" in the rural tourist area of Guilinggu, Luchuan County, Guangxi. Photo by Chen Guanyan

　　Xie Xiaoqin, a tourist from Yulin City, said that it is not surprising that the "Baziling Sightseeing Great Wall" attracted attention because it imitated the famous Badaling Great Wall. But it doesn’t have the cultural background of Badaling Great Wall, and it doesn’t tap the local characteristics. It’s hard to say how long it will be popular.

　　Ms. Luo, a tourist from Guangzhou, has been to the Badaling Great Wall in Beijing. She thinks that the "Baziling Great Wall" can’t be compared with the Badaling Great Wall, but for local people, the construction of the "Little Great Wall" can bring new leisure tourism projects, which is also good.

　　On November 23rd, tourists visited the "Baziling Great Wall" in Guilinggu rural tourist area, Luchuan County, Guangxi. Photo by Chen Guanyan

　　The project leader responds to the dispute.

　　Ruan Guansheng doesn’t care about these disputes. Ruan Guansheng said that the Great Wall of Wan Li is a famous tourist attraction and a place that Chinese yearns for. When she was in her seventies, my mother urged me to take her to the Badaling Great Wall in Beijing. However, it is a long way from Guangxi to Beijing and the cost is high. Many people, especially the elderly, rarely have the opportunity to experience climbing the Great Wall.

　　On November 23rd, aerial photography was taken of the "Baziling Great Wall" in Guilinggu rural tourist area, Luchuan County, Guangxi. Photo by Chen Guanyan

　　Ruan Guansheng introduced that Gao Qing Village is one of the second batch of key rural tourism villages in China. The rural tourism project of Guilinggu, located in Baziling, Gao Qing Village, covers an area of more than 130 hectares, and is planted with economic trees such as camellia oleifera, orange peel and camellia chrysantha, with an original ecological forest landscape stretching for dozens of miles, forming a new development path of "characteristic industry+characteristic tourism".

　　Over the years, Guilinggu Rural Tourism Zone has absorbed 72 poor households in the village to participate in rural tourism poverty alleviation industry, and implemented the model of villagers’ cooperatives+tourism enterprises+poor households to develop and expand tourism, providing a platform for poor households to get rid of poverty and increase their income.

　　On November 23rd, aerial photography was taken of the "Baziling Great Wall" in Guilinggu rural tourist area, Luchuan County, Guangxi. Photo by Chen Guanyan

　　Ruan Guansheng is a native of Gao Qing village. He worked in architecture in his early years and has some experience. He thought that Baziling Mountain was very suitable for building a sightseeing corridor, so he came up with the idea of building a condensed version of the Great Wall. "One is to satisfy the villagers’ desire to climb the Great Wall, and the other is to increase the attractions for rural tourism and promote tourism development, thus helping poor households to increase their income."

　　On November 23rd, tourists visited the "Baziling Great Wall" in Guilinggu rural tourist area, Luchuan County, Guangxi. Photo by Chen Guanyan

　　Ruan Guansheng said that Luchuan County has a good geographical location. In September this year, the Yulin-Zhanjiang Expressway in Guangxi was fully opened to traffic, making it very convenient for Guangdong tourists to travel to Luchuan County by car. In the future, the "Baziling Great Wall" will attract more tourists from Guangdong Province and even all over the country to experience it. "We are accelerating the improvement of tourism infrastructure and preparing for receiving more tourists."

　　Author: Chen Qiuxia Chen Guanyan

[Network+] China basketball finally won the first world championship in adult competition! In the women’s final of the 2019 FIBA Three-Man Basketball World Cup held in the early morning of 24th, the China women’s team beat the Hungarian team, a European powerhouse, by 19:13 to win the championship. Last night’s "News Network" broadcast this good news.

When it comes to basketball games, the first thing we usually think of is 5X5, that is, five players from each side will play in four sessions with 10 minutes each (12 minutes for NBA and CBA). The public is much more unfamiliar with three-person basketball, and more may only stay in "knowing" that there is a KFC national youth three-person basketball championship challenge that has been held for 15 years in a row. Today, Lianjun will tell you about the "past life" of this sport.

Indeed, compared with the history of more than 100 years of five-a-side basketball competition, the popularity and popularity of three-a-side basketball, which was first played in world-class competition in 1992, is indeed much inferior. However, because it does not need much space (half of the five-person system), the single game time is short (10-16 minutes per game), and it is more suitable for training beginners’ technical movements and technical and tactical cooperation, it is very popular among young students.

In recent years, 3X3 basketball has made more and more appearances in the world. The FIBA Three-Man Basketball World Cup, which was won by the China women’s team, has been held for six times since it was first held in 2012. In 2017, the International Olympic Committee officially added the three-person basketball game to the Olympic Games.

After winning the World Cup, the China women’s team also successfully won the Olympic tickets, and we will see them again at the Tokyo Olympic Games next year.

"Many skills of three-person basketball and five-person basketball are the same. Whoever can put more balls into the basket will win." David Crocker, executive director of FIBA, once explained this sport. However, the difference between skills and actual combat also makes them have their own characteristics. From some angles, they can also be two completely different sports.

Only three players are present, which means it is difficult to distinguish the roles of "striker" and "defender", so everyone should get used to playing the role of generalist. The shrinking of the venue makes the confrontation more intense and the play faster. It is enough for each team to have four good players when three people play. Compared with the five-a-side basketball game, each team needs 8-12 excellent players to attack the medals. This game is undoubtedly more suspenseful, and anyone can become a winner.

Such suspense also makes it more possible for China to play three-person basketball in the future.

In the field of five-a-side basketball, China can’t be called a traditional strong team. Previously, China’s best performance in the world was the runner-up of the women’s team at the 1992 Barcelona Olympic Games. Although the men’s basketball team won the eighth place in four Olympic Games, it is always difficult to take a step forward.

But the situation is much better in three-person basketball. If you count the youth competitions, China won the championship as early as 2010. In the first World Youth Olympic Games, China U17 women’s three-person basketball team beat all the strong teams and finally won the gold medal. At last year’s Asian Games in Jakarta, the men’s and women’s teams of China swept the championship in this event. This makes us have more expectations for next year’s Olympic Games.

It is worth mentioning that, due to the good mass foundation, the three-person basketball game has more advantages in talent selection than the five-person basketball game, which also lays an excellent foundation for the future development of this project.

The four players of the men’s basketball team that won the championship in the Asian Games last year can be called "grassroots": Huang Wenwei, who scored the winner in the final, is a teacher of Guangzhou Institute of Physical Education, xiao hailiang is an employee of Dongguan Cultural and Sports Bureau, Zeng Bingqiang is a student of Guangdong University of Technology, and Chen Gong is from Hubei team, but so far, he has not played in the professional league. And they were able to get on the stage of the competition, all through the "I want to go to the Olympics" three-person basketball competition held in chinese basketball association at the beginning of last year.

After the two words "all the people" and "Olympic Games" are closely linked, China three-person basketball will surely enter a better era.

　　This report is compiled in accordance with Article 50 of the Regulations of People’s Republic of China (PRC) Municipality on the Openness of Government Information (hereinafter referred to as the Regulations on the Openness of Government Information).

　　I. General situation

　　In 2021, the Changping District Government earnestly implemented the Regulations on the Openness of Government Information, continuously expanded the open content, innovated the open forms, improved the open system, strengthened the open supervision, and promoted the open work of government information and government affairs in an orderly manner.

　　(A) the implementation of open process specification

　　The first is to compile the "Changping District Government Information and Government Affairs Disclosure Work System Manual", refine nine system rules, and standardize the government affairs disclosure work process in the whole region. The second is to strengthen the voluntary disclosure of government information, standardize the setting of government information disclosure columns, and timely release the statutory voluntary disclosure content. Special topics such as "the construction of two districts" were established, and information in key areas such as the approval and implementation of major construction projects, the allocation of public resources, people’s livelihood, law enforcement supervision, and urban and rural construction was actively disclosed, and 3,401 pieces of information were released throughout the year. The third is to optimize the mechanism of disclosure according to the application, and actively respond to the needs of enterprises for government information disclosure. The whole region has handled 923 applications for government information disclosure. The fourth is to strengthen the business guidance for the open work of all units, combine the online business training of the universality of government affairs disclosure with the offline analysis and discussion according to the application difficulties, and promote the continuous improvement of the standardization level of government information and government affairs disclosure in the whole region.

　　(2) Strengthen the management of open platforms.

　　First, strengthen the construction of the website platform of the district government and improve the application efficiency of data classification management of government websites. Strengthen the construction of information content on government websites to ensure timely information release and update. The second is to complete the development and testing of the "Pingping" function module of the government service intelligent robot and the development of WeChat applet, expand the knowledge base data by more than 14,000 pieces, realize the voice interaction function, and provide instant question and answer service for the enterprise masses. The third is to strengthen the application of cutting-edge monitoring and inspection technologies such as big data and cloud monitoring, refine the assessment rules for new government media, and implement the monthly notification system for government websites and new government media work.

　　(3) Improve the interaction mechanism between the government and the people

　　The first is to expand public participation in policy formulation. For policy documents concerning people’s interests and people’s livelihood, the function of "I want to make suggestions" is set to collect people’s opinions and give play to the role of public participation in the process of policy formulation. The second is to intensify the policy interpretation, and interpret 17 district-level policy documents in an easy-to-understand way, such as illustrated cases, policy questions and answers, videos, etc., so that enterprises can understand and understand them well. Third, we will actively carry out a series of activities of "I do practical things for the masses", hold four "policy public lectures" and 11 "government open days" around optimizing the business environment, improving people’s livelihood and safe production, strengthen the interactive communication between the government and the people, and guide the public to participate in social governance in an orderly manner.

　　(D) to strengthen the assessment and supervision.

　　Incorporate government information and government affairs disclosure into the performance appraisal scope of the district government, and further optimize the appraisal rules. Carry out third-party evaluation of government information and government affairs disclosure on a quarterly basis, and report the evaluation results. There was no accountability in the whole year.

　　Second, the initiative to disclose government information

　　Iii. Receiving and handling applications for government information disclosure

　　Four, the government information disclosure of administrative reconsideration and administrative litigation.

　　V. Main Problems and Improvements

　　The main problems are as follows: First, the disclosure of government information by various units lacks depth and breadth, and the disclosure ratio of government information concerned by enterprises and the masses is not high. Second, the underlying content management platform system of government websites cannot fully meet the requirements of intelligent and digital applications of government websites. The operation and maintenance management of new government media is not standardized. Third, the staff’s professional ability needs to be improved, and the work norms and standards need to be further strengthened.

　　Improvement: First, we will promote the integrated development of government information, government affairs disclosure and government affairs service, combine the disclosure of statutory contents of government information with the disclosure of information needed for handling affairs, and promote the whole process of handling services to fully meet the personalized service needs of handlers. The second is to continuously upgrade and explore the in-depth application of new technologies in the government information disclosure platform, and promote the integrated development of government websites and government new media knowledge bases. The third is to establish a normalization mechanism for government information and government affairs publicity training, form good measures into typical cases, adopt video, offline meetings and other forms of experience exchange, earnestly do a good job in business guidance, and improve the business ability of government information and government affairs publicity staff in all units in the region.

　　Vi. Other matters that need to be reported

　　This unit collects information processing fees according to the Measures for the Administration of Information Processing Fees for Government Information Disclosure. In 2021, there were 0 pieces of charge notices, with a total amount of 0 yuan. The total amount actually collected is 0 yuan.

Xi ‘an Jansen became history, Novartis spun off Sandoz, Pfizer Vaccine Division changed coaches, and Abbey’s position as the "king of medicine" was not guaranteed … Since September, many multinational pharmaceutical companies have experienced great changes from personnel to department structure to R&D pipeline.

Over the years, Greater China has been an important market component of many multinational pharmaceutical companies, and it is also the main driving force for their performance contribution. In the post-epidemic period, factors such as the difficulty in research and development of innovative drugs, declining performance, fierce competition in the same industry and continuous changes in industry policies are all affecting the strategic adjustment and personnel changes of multinational pharmaceutical companies in China. How to go in the second half of 2023? These pharmaceutical companies have taken the lead in making adjustments.

Johnson & Johnson: The History of Xi ‘an Janssen

The brand rejuvenation of the former giant Johnson & Johnson attracted the most attention. On September 14th, Johnson & Johnson announced that it would integrate its medical technology and pharmaceutical businesses into Johnson & Johnson’s name. Among them, Jansen changed its name to Johnson & Johnson Innovative Pharmaceutical, which also means that the logo of "Xi ‘an Jansen" will become history.

Once upon a time, the advertisement of Xi ‘an Jansen, "Stomach power is insufficient, please help with motilium", went deep into thousands of families in China, so that its Dakening, Sismin, Caile, Tylenol … all became necessities at home. The history of Xi ‘an Jansen dates back to 1961, when the Belgian scientist Dr. Paul Jansen joined Johnson & Johnson with his Janssen Pharmaceutical Companies. Since then, the strength of the Johnson & Johnson pharmaceutical sector has been greatly enhanced, and the research and development of prescription drugs has also been on the right track. However, after 2002, the OTC products that Xi ‘an Jansen relied on for a living began to decline. The fundamental reason was that the original star products, Motilium and Dyclonine, were already in the decline period of product life cycle, and the follow-up new products were unsustainable. Johnson & Johnson Group never gave Xi ‘an Jansen any new product support.

In 2021, under the pressure of cost, Johnson & Johnson began to carry out drastic reforms, divesting the consumer health business and listing it independently, becoming a dual-business company spanning the two major sectors of medical equipment and medicine. This series of reforms has also kept its performance growing in recent years. The semi-annual report in 2023 showed that its total revenue exceeded the $50 billion mark, among which the revenue of pharmaceutical business in the first half of the year increased by 3.7% year-on-year to $27.144 billion. Immunity and tumor were the main sources of performance in Johnson & Johnson’s pharmaceutical business.

In the future, Johnson & Johnson will focus more on the fields of tumor, immunity, nerve, cardiovascular, pulmonary hypertension and retina, and develop cutting-edge drugs. In terms of personnel structure, Joseph Wolk, chief financial officer of Johnson & Johnson, said last year that due to economic pressure and the separation plan of consumer health business, Johnson & Johnson may moderately reduce the number of employees.

Pfizer: structural adjustment

Since September, the structure of Pfizer China’s Hospital Emergency Division and Vaccine Division, as well as the changes of relevant responsible persons, have come into effect. Among them, the head of the Vaccine Division changed from Zhang Lingyan to Yang Bei, and there are North China District, South China District and Market Platform under the charge of Hao Yikai, Shi Yinli and Jin Xinqing respectively. It is understood that although Yang Bei is the new leader of the Vaccine Division, she has been working in Pfizer for 25 years, and the other three responsible persons have been in Pfizer for more than ten years.

Some insiders speculate that the coaching change of Pfizer Vaccine Division may be related to the performance pressure of its vaccine products. According to Pfizer’s forecast, the revenue of its two major COVID-19 products, vaccine (Comirnaty) and oral medicine (Paxlovid), will be about $13.5 billion and $8 billion in 2023, respectively, down by 64% and 58% compared with 2022, and the gross profit of COVID-19 vaccine will be equally divided with BioNTech.

At the same time, another star product of Pfizer, 13-price pneumonia vaccine Pei Er 13, successfully expanded its age in April this year, but with the catch-up of domestic pharmaceutical companies, Pei Er 13 is no longer the only choice in the China market. In 2020 and 2021, watson biological’s Woanxin and Minhai Bio’s Weimin Feibao were listed successively, and the prices were 598 yuan/dose and 458 yuan/dose respectively, which were significantly lower than Pei Er’s 698 yuan/dose. And as early as before Pei Er’s 13th birthday, the vaccination targets of Woanxin and Weimin Feibao were infants and children from 6 weeks to 5 years old (before the 6th birthday).

However, judging from the coaching change, Pfizer remains optimistic about the vaccine field and the China market. According to the data of the semi-annual report, Pfizer increased the cost of vaccine product research and development by 530 million US dollars in the first half of this year. As of June this year, Pfizer has 12 vaccines under research, and 1/3 of them have entered Phase III clinical practice.

Lilly: preparing for diet pills

On October 1st, Yuan Ping, the current acting head of Lilly’s Diabetes Alliance Division, was appointed as the national executive sales director of Diabetes Portfolio Division, and the head of Diabetes Alliance Division was replaced by Liu Aihua, the current head of Cancer Portfolio Division. This change may be a warm-up for the launch and promotion of the slimming and hypoglycemic drug telpotide in the second half of this year.

The semi-annual report shows that Lilly’s total revenue in the first half of the year was 15.272 billion US dollars, up about 7% year-on-year; The net profit was US$ 3.108 billion, up about 9% year-on-year, of which Telpotide achieved sales of US$ 980 million. Not only has the performance increased significantly, but under the expectation of diet pills and new drugs for Alzheimer’s disease, as of September 25th, Lilly’s total market value has reached as high as $524.3 billion, with a share price of $522. Telpotide, like Novo Nordisk’s Smegrupeptide and Liraglutide, belongs to the most popular GLP-1 drugs at present. The indications for weight loss of Lilly Telpotide injection were declared and listed in China in August, and it is expected to be listed at the end of the year.

Abbey: Looking for the Next "King of Medicine"

Recently, AbbVie terminated two agreements with innovative pharmaceutical companies in China. Tianjing Bio announced on September 22nd that AbbVie had terminated the agreement with lemzoparlimab, a candidate drug for CD47 antibody jointly developed and sold by the company in 2020, and the termination agreement will take effect on November 20th this year. It is understood that CD47 is another hot target after PD-1. Another project that was terminated was an authorized cooperation between AbbVie and Jiakesi Pharmaceutical, a domestic biopharmaceutical company, on SHP2 inhibitors. Garcos announced the termination of the project in July this year, and within 180 days of handover, AbbVie will continue to reimburse all expenses under the pre-approved development plan.

Many people were surprised by AbbVie’s decision to give up two innovative drugs from China. Some insiders speculate that it is because clinical trials have not reached expectations. In order to save costs, it is reasonable for AbbVie to give up these two projects.

In the past 20 years, Hummel, the "drug king", has brought more than $200 billion in revenue to AbbVie. However, at the beginning of this year, Amjevita, the first bio-similar drug of Hummel, officially entered the American market. In addition, nine bio-similar drugs competed with Hummel, resulting in a decline in its sales. In the first quarter of this year, AbbVie’s revenue was US$ 12.225 billion, down over 8% year-on-year, while Hummel’s revenue was US$ 3.541 billion, down over 20% year-on-year. AbbVie previously predicted that the franchise of Hummel will be eroded by about 45% in 2023, and AbbVie, who is eager to find the next "drug king", has been forced to terminate the research and development of seven ADC drugs.

Roche: Layout "New Troika"

Chen Shaofeng, the head of Roche’s specialty medicine field (ophthalmology, neuroscience, anti-infection and immunity) in China, resigned at the end of July. Since August 31st, Chen Kaijuan, the head of global integration strategy of Sufuda in Roche headquarters, has taken over the position of head of specialty medicine field, reporting directly to Bian Xin, president of Roche China.

Since last year, Roche has continuously optimized its strategic product portfolio in China. With the patent protection of "Troika" of Avastin, Herceptin and Rituximab expiring one after another, Roche is laying out a new "Troika", that is, expanding from a single tumor field to three major fields of "tumor, neuroscience and ophthalmology".

To this end, Roche has announced an additional investment of nearly 250 million yuan in China as working capital. Including this investment, Roche has invested a total of 1.4 billion yuan in the China market in three years. At present, Roche’s investment has achieved initial results. According to the data of the semi-annual report, Roche’s total business income was 22.681 billion Swiss francs (about 181.624 billion yuan), an increase of 8% year-on-year; Among them, the pharmaceutical business income in China was 1.505 billion Swiss francs (about RMB 12.052 billion), up 3% year-on-year, accounting for 6.6% of Roche’s global pharmaceutical business income.

Sanofi: Stick to the "Slimming Plan"

On August 31st, Sanofi, a French pharmaceutical giant, announced that Bill Hibbard, the head of its global specialty drugs, had resigned. On September 18th, Sanofi sold its 11 central nervous system products to Pharmanovia, another multinational pharmaceutical company.

In the past two years, Sanofi has been actively "slimming" by selling consumer health care brands and 17 drugs in the fields of central nervous system diseases and vascular diseases. This series of "sale plans" has been advocated by Paul Hudson, the current CEO of Sanofi, since he took office. In 2019, he put forward the "play to win" plan, aiming to focus Sanofi’s business on key research and development fields such as immune inflammation, rare diseases, tumors and vaccines from 2020 to 2025.

At present, the slimming plan has not changed. As of the first half of this year, Sanofi has at least 78 clinical projects, most of which are concentrated in the above key areas. According to the semi-annual report, Sanofi’s sales in the first half of this year reached 20.187 billion euros (about 156.389 billion yuan), a year-on-year increase of 2%. Among them, the core product, that is, Duplex monoclonal antibody in the self-exemption field, sold 4.878 billion euros (about 37.77 billion yuan). Two new drugs approved last year: Enjaymo, which is used to reduce the demand for red blood cell transfusion caused by hemolysis in adults with cold agglutinin’s disease (CAD), and Xenpozyme, which is used in children and adult patients with acid sphingomyelinase deficiency (ASMD), have achieved an increase in volume, with an increase of 1800% and 750% respectively in the first half of the year. It can be seen that after getting rid of the non-main business, Sanofi has played a "home court advantage" more easily.

Novartis: Spinning off Generic Drug Subsidiary

On September 15th, Novartis announced that on October 4th, Sandoz, a subsidiary of Novartis, which specializes in generic drugs and bio-similar drugs, was officially split.

It took Novartis nearly five years to divest Sandoz. The initial split news came out in 2018, when Sandoz’s performance showed a downward trend and dragged down Novartis. Although Sandoz, Tiwa and Huizhi dominate the world’s top three in the field of generic drugs, Sandoz’s generic drugs brought Novartis only one-fifth of the total revenue in 2022, and the rest were created by innovative drugs. The data shows that in 2022, the revenue of Novartis innovative drugs was 41.296 billion US dollars, accounting for 82% of its total revenue; Sandoz’s revenue is $9.249 billion.

In order to become a truly innovative drug company, Novartis has been split up in recent years. In addition to Sandoz, Novartis also split Alcon, one of the largest ophthalmic products and equipment companies. In addition, in the field of treatment, Novartis has also focused on cardiovascular, kidney and metabolism, immunity, neuroscience and tumor from more than 10 original concerns.

At present, Novartis is moving towards the goal of being the largest innovative pharmaceutical company in the world. In the first half of this year, Novartis’s net sales were US$ 26.575 billion (about RMB 194.314 billion), a year-on-year increase of 5%; The net profit was US$ 4.611 billion (about RMB 33.715 billion), a year-on-year increase of 32%.

Immena: poor performance for "veteran"

Inmina, the leader in gene sequencing, announced on September 20th that Li Qing, the company’s global senior vice president and general manager of Greater China, had left. The day before, Waters announced the appointment of Li Qing as the company’s vice president and general manager of Greater China.

Imina is a global leader in gene sequencing and chip technology, and its product line covers scientific analysis instruments such as sequencing platforms, chip scanners and in-vitro diagnostic sequencers. But in recent years, the performance in China market is not good. In the fourth quarter of 2022, the revenue of Mina China dropped by 22%, and in the first quarter of 2023, the revenue dropped by 28% to 91 million US dollars (about 665 million yuan). According to this year’s semi-annual report, in the second quarter, Mina’s performance in China was still declining, and its revenue was US$ 115 million (about RMB 841 million), down 3% year-on-year.

In this regard, Immena explained that global inflation, exchange rate, slowing economic growth, and market competition have caused poor performance. Now that "veteran" Li Qing has gone, the challenge is still there, because it is still unknown whether Mina’s performance will pick up in the second half of the year.

GSK: R&D has been frustrated repeatedly

Recently, GSK announced that Dr. John Lepore, Senior Vice President and Director of R&D, had left the company. Dr. Kaivan Khavandi, the new R&D director who will succeed him, will lead GSK’s restructured respiratory and immunology department. On September 11th, WestlyYu, the current vice president of GSK China and head of respiratory business, was appointed as vice president and head of special medicine business, and continued to be one of the leading teams of GSK China, reporting directly to Qi Xin, general manager of GSK China. There are indications that the GSK changes not only personnel, but also internal structure and research and development direction.

In recent years, GSK has had a hard time, especially in the research and development of new drugs with high investment and high risk. In November 2022, an ADC drug under GSK was stopped by the FDA; In February of this year, the CEO of GSK announced that he would end all investment in gene therapy; In addition, GSK’s PD-1 drug Jemperli, which was acquired by acquiring Tesaro for $5.1 billion, sold only $8 million in the first half of 2022, far below GSK’s expectations.

GSK’s executive adjustment may be to change the status quo of making ends meet. GSK divides the R&D department into three groups: respiratory and immunology, vaccines and infectious diseases, and oncology, which are dedicated to initial discovery and early clinical research. GSK also said that it will not reduce investment in research and development, and will accelerate the development of products in the future.

AstraZeneca: Increase investment in China.

According to the British "Daily Mail" reported on September 10th, the CEO of AstraZeneca may leave as soon as next year. Although changes are on the way, AstraZeneca’s development in China is becoming more and more "localized". In 2023, AstraZeneca celebrated its 30th anniversary in China. Over the past 30 years, the China market has become increasingly important in AstraZeneca’s global strategic position, with R&D investment in China reaching 1.5 billion US dollars and investment exceeding 1 billion US dollars. At present, China has developed into AstraZeneca’s second largest market in the world, and is gradually changing from the original "main sales place" to "main production place" and "main creation place".

Following the formal signing of the domestic production and supply base of Budigefu inhalation aerosol with a total investment of about 450 million US dollars with Qingdao High-tech Zone on March 25th this year, AstraZeneca planned to invest another 250 million US dollars in Qingdao inhalation aerosol production and supply base project on August 14th, in order to increase the canning production capacity and build an inhalation aerosol packaging production line, and further expand the production and supply base capacity. In addition, it is reported that AstraZeneca will also set up a research and development center in Hong Kong.

Bayer and Bojian: A wave of layoffs is coming.

On September 15th, it was reported in Reuters that Bill Anderson, CEO of Bayer, was considering cutting management, and the specific plan will be put forward at the recent internal strategy meeting. On the same day, Oliver Kohlhaas, head of Bayer strategy, announced his resignation.

Although Bayer’s global spokesman declined to comment, Bayer’s layoffs have already begun. In February of this year, Bayer launched the "Resignation Option Plan" in California, USA, which laid off 55 employees who were over 55 years old and had served for 10 years. In August, BlueRock Therapeutics, a cell therapy company owned by Bayer, announced that it would lay off about 50 employees. In addition, since 2023, Bayer’s share price has only increased by 6%, far less than its peers, and Novartis’s share price has increased by 18% in the same period. It is reported that in the next few months, Bayer will formulate a more official comprehensive restructuring plan to boost the company’s share price, and many investors hope that it can split the two major departments of agriculture and medicine and go public independently.

Bayer is not the only one to reduce costs and increase efficiency. In July, Bojian, who just made a major breakthrough in the field of drugs for Alzheimer’s Harmo, announced that it would try to save $1 billion in operating expenses by 2025 by laying off 1,000 people and stopping the research and development of at least four drugs, and spend $300 million of it on the research and development of new drugs.

Survival, operational efficiency and clinical demand have always been the three driving forces for the continuous reform of domestic and foreign pharmaceutical companies. The reform and adjustment of multinational pharmaceutical companies are also inseparable from these three factors. In addition, in the face of a more complex and huge China market, it will take more effort. How innovative drugs can enter medical insurance, how to promote them after entering medical insurance, and how to compete with similar products have forced multinational pharmaceutical companies to make constant adjustments in structural changes, internal resources and key teams.

At present, the policy that has the greatest impact on the performance of pharmaceutical companies in the second half of the year is undoubtedly the medical anti-corruption action that is expected to last for one year. Tang Aijin, chief analyst of Cinda Securities Medicine, believes that medical anti-corruption will affect the sales rhythm in the short term, but it will not be broken. Strengthening the restriction and supervision of the whole industry will benefit the long-term healthy development of the industry, and pharmaceutical companies will pay more attention to R&D and innovation after the sales expenses are limited.